Dr. Goldman pointed out that efficacy, safety, and tolerability of most DMTs are unknown in patients with comorbidities such as obesity or cardiovascular disease. “It’s important to remember that for many patients with comorbidity, these are exclusion criteria in the clinical trials program,” she said. “So while we know that having comorbidities in an MS population does affect quality of life and increase disability progression, what we are lacking understanding [about] is how these may affect treatment response.”
Dr. Goldman disclosed that she is a consultant and advisory board member for Questcor Pharmaceuticals.
The session was sponsored by an educational grant from Biogen.
On Twitter @dougbrunk